Scinai Immunotherapeutics (SCNI) Cash & Current Investments (2016 - 2025)

Scinai Immunotherapeutics has disclosed Cash & Current Investments across 10 years of filings, most recently posting $2.0 billion for Q4 2025.

• Cash & Current Investments for Q4 2025 came in at $2.0 billion, up 96900.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 billion (up 96900.0% YoY), and the FY2025 annual result was $2.0 billion, up 96900.0% from the prior year.
• Cash & Current Investments came in at $2.0 billion for Q4 2025 at Scinai Immunotherapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $48.6 billion in Q1 2021 to a low of $1.1 million in Q2 2025.
• The 5-year median for Cash & Current Investments is $8.0 million (2022), against an average of $2.8 billion.
• Across the five-year window, Cash & Current Investments jumped 114285278.19% in 2021 and sank 99.97% in 2022, its largest moves.
• Scinai Immunotherapeutics' Cash & Current Investments stood at $17.5 million in 2021, then dropped by 18.85% to $14.2 million in 2022, then slumped by 64.76% to $5.0 million in 2023, then sank by 58.18% to $2.1 million in 2024, then surged by 96900.0% to $2.0 billion in 2025.
• The last three Cash & Current Investments figures came in at $2.0 billion (Q4 2025), $1.1 million (Q2 2025), and $2.1 million (Q4 2024), per Business Quant data.